Used primarily in research settings, this PROTAC (Proteolysis Targeting Chimera) compound plays a crucial role in targeted protein degradation. It is designed to specifically degrade BET proteins, which are involved in regulating gene expression. By doing so, it helps in studying the effects of BET protein inhibition in various diseases, particularly cancer. Researchers utilize it to explore potential therapeutic strategies that involve the selective removal of disease-causing proteins, offering a novel approach to drug development. Its application is significant in understanding the molecular pathways and mechanisms that could be targeted for treating conditions linked to abnormal gene expression.